

MEDIMMUNE INC /DE

Form S-8 POS

June 26, 2007

As filed with the Securities and Exchange Commission on June 26, 2007

**Registration No. 333-88835**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549



**POST-EFFECTIVE AMENDMENT NO. 2 ON FORM S-8 TO  
FORM S-4 REGISTRATION STATEMENT NO. 333-88835**



**Under**



**The Securities Act of 1933**



**MedImmune, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation or Organization)

**55-1555759**

(I.R.S. Employer  
Identification Number)

**One MedImmune Way**

Gaithersburg, MD 20878

(301) 398-0000

Edgar Filing: MEDIMMUNE INC /DE - Form S-8 POS

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)





**1999 Incentive Compensation Plan**

**1987 Incentive Stock Option Plan**

**1987 Non-Statutory Stock Option Plan**

**1991 Special Non-Statutory Stock Option Plan**

**1987 Special Non-Statutory Stock Option Plan**

**1992 Stock Option Plan**

**1996 Non-Employee Directors Stock Option Plan**



**Non-Executive Stock Option Plan**

of U.S. Bioscience, Inc.

(Full Titles of the Plans)



**David M. Mott**

**Chief Executive Officer, President**

**MedImmune, Inc.**

**One MedImmune Way**



Gaithersburg, MD 20878

(301) 398-0000

Edgar Filing: MEDIMMUNE INC /DE - Form S-8 POS

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)





**DEREGISTRATION OF UNSOLD SECURITIES**

This Post-Effective Amendment No. 2 relates to the following Registration Statement on Form S-4 of MedImmune, Inc. (the Company ) (the Registration Statement ):

File No. 333-88835, which was filed with the Securities and Exchange Commission (the SEC ) and became effective on October 21, 1999, as amended by Post-Effective Amendment No. 1 pertaining to the registration of 752,433 shares of common stock, par value \$0.01 per share of the Company ( Common Stock ), which was filed with the SEC and became effective on November 23, 1999.

On April 22, 2007, the Company, AstraZeneca PLC, a public limited company incorporated under the laws of England and Wales ( Parent ), and AstraZeneca Biopharmaceuticals Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ( Purchaser ), entered into an Agreement and Plan of Merger pursuant to which Purchaser merged with and into the Company, with the Company surviving as an indirect wholly owned subsidiary of Parent (the Merger ). The Merger became effective on June 18, 2007 as a result of the filing of a certificate of ownership and merger effectuating the Merger with the Secretary of State of the State of Delaware.

As a result of the Merger, the offering pursuant to the Registration Statement has been terminated. In accordance with undertakings made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company registered but unsold under the Registration Statement.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, MedImmune, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 2 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Gaithersburg, State of Maryland, on June 26, 2007.

MEDIMMUNE, INC.

By: /s/ David M. Mott  
Name: David M. Mott  
Title: Chief Executive Officer and President

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 has been signed by the following persons, in the capacities indicated, as of June 26, 2007.

<b>Signature</b>	<b>Title</b>
/s/ David M. Mott Name: David M. Mott	Chief Executive Officer and President
/s/ Lota S. Zoth Name:Lota S. Zoth	Chief Financial Officer and Senior Vice President
/s/ Glenn M. Engelmann Name: Glenn M. Engelmann	Director
/s/ Shaun F. Grady Name: Shaun F. Grady	Director
/s/ Christopher R. W. Petty Name: Christopher R. W. Petty	Director